Histiocytoses

Oncology of Infancy and Childhood: Expert Consult - Online and Print

Volumn , Issue , 2009, Pages 963-988

  Degar, Barbara A ^a,b   Fleming, Mark D ^a,b   Rollins, Barrett J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70450147888     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3431-5.00024-8     Document Type: Chapter

References (281)

1. G Girolomoni, C Caux, S Lebecque, et al. (2002) Langerhans cells: still a fundamental paradigm for studying the immunobiology of dendritic cells. Trends Immunol. 23 6-8
2. K Shortman and SH Naik (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7 19-30
3. RM Steinman and H Hemmi (2006) Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311 17-58
4. S Yamazaki, K Inaba, KV Tarbell and RM Steinman (2006) Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol Rev 212 314-329
5. H Hemmi, M Yoshino, H Yamazaki, et al. (2001) Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-beta1-dependent cells. Int Immunol 13 695-704
6. S Henri, D Vremec, A Kamath, et al. (2001) The dendritic cell po­pulations of mouse lymph nodes. J Immunol 167 741-748
7. T Jakob, J Ring and MC Udey (2001) Multistep navigation of Langerhans/dendritic cells in and out of the skin. J Allergy Clin Immunol 108 688-696
8. A Kissenpfennig, S Henri, B Dubois, et al. (2005) Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22 643-654
9. MC Dieu, B Vanbervliet, A Vicari, et al. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188 373-386
10. F Sallusto, P Schaerli, P Loetscher, et al. (1998) Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28 2760-2769
11. NS Wilson, D El-Sukkari, GT Belz, et al. (2003) Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102 2187-2194
12. D Vremec, J Pooley, H Hochrein, et al. (2000) CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol 164 2978-2986
13. GW Mierau, BE Favara and JM Brenman (1982) Electron microscopy in histiocytosis X. Ultrastruct Pathol 3 137-142
14. J Valladeau, O Ravel, C Dezutter-Dambuyant, et al. (2000) Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 12 71-81
15. AC Gavino, JS Chung, K Sato, et al. (2005) Identification and expression profiling of a human C-type lectin, structurally homologous to mouse dectin-2. Exp Dermatol 14 281-288
16. K Inaba, WJ Swiggard, M Inaba, et al. (1995) Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 163 148-156
17. JF Emile, J Wechsler, N Brousse, et al. (1995) Langerhans cell histiocytosis: definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol 19 636-641
18. J Diao, E Winter, C Cantin, et al. (2006) In situ replication of immediate dendritic cell (DC) precursors contributes to conventional DC homeostasis in lymphoid tissue. J Immunol 176 7196-7206
19. SH Naik, D Metcalf, A van Nieuwenhuijze, et al. (2006) Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 7 663-671
20. M Colonna, G Trinchieri and YJ Liu (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5 1219-1226
21. F Sallusto and A Lanzavecchia (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 1109-1118
22. MG Manz, D Traver, T Miyamoto, et al. (2001) Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97 3333-3341
23. D Traver, K Akashi, M Manz, et al. (2000) Development of CD8alpha-positive dendritic cells from a common myeloid progenitor. Science 290 2152-2154
24. L Wu, A D’Amico, H Hochrein, et al. (2001) Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 98 3376-3382
25. KP MacDonald, V Rowe, HM Bofinger, et al. (2005) The colony-stimulating factor 1 receptor is expressed on dendritic cells during differentiation and regulates their expansion. J Immunol 175 1399-1405
26. N Onai, A Obata-Onai, R Tussiwand, et al. (2006) Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J Exp Med 203 227-238
27. AT Kamath, J Pooley, MA O’Keeffe, et al. (2000) The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 165 6762-6770
28. F Ginhoux, F Tacke, V Angeli, et al. (2006) Langerhans cells arise from monocytes in vivo. Nat Immunol 7 265-273
29. I Mende, H Karsunky, IL Weissman, et al. (2006) Flk2+ myeloid progenitors are the main source of Langerhans cells. Blood 107 1383-1390
30. NV Serbina and EG Pamer (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7 311-317
31. U Yrlid, CD Jenkins and GG MacPherson (2006) Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol 176 4155-4162
32. DK Fogg, C Sibon, C Miled, et al. (2006) A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311 83-87
33. G Janka, S Imashuku, G Elinder, et al. (1998) Infection- and malignancy-associated hemophagocytic syndromes: secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 12 435-444
34. KE Nichols, RM Egeler, VH Perry and R Arceci (2003) Summary of the 12th Nikolas Symposium dendritic cell differentiation: signals, signaling and functional consequences as clues to possible therapy. J Pediatr Hematol Oncol 25 193-197
35. CL Willman, L Busque, BB Griffith, et al. (1994) Langerhans-cell histiocytosis (histiocytosis X): a clonal proliferative disease. N Engl J Med 331 154-160
36. CL Willman and KL McClain (1998) An update on clonality, cytokines, and viral etiology in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 12 407-416
37. RC Yu, C Chu, L Buluwela and AC Chu (1994) Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 343 767-768
38. DR Betts, KE Leibundgut, A Feldges, et al. (1998) Cytogenetic abnormalities in Langerhans cell histiocytosis. Br J Cancer 77 552-555
39. M Weintraub, KG Bhatia, RS Chandra, et al. (1998) p53 expression in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 20 12-17
40. RD Alston, RG Tatevossian, RJ McNally, et al. (2007) Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer 48 555-560
41. A multicentre retrospective survey of Langerhans cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans Cell Histiocytosis Study Group. Arch Dis Child 75 17-24
42. A Guyot-Goubin, J Donadieu, M Barkaoui, et al. (2008) Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer 51 71-75
43. H Stalemark, E Laurencikas, J Karis, et al. (2008) Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 51 76-81
44. SE Kilpatrick, DE Wenger, GS Gilchrist, et al. (1995) Langerhans cell histiocytosis (histiocytosis X) of bone: a clinicopathologic analysis of 263 pediatric and adult cases. Cancer 76 2471-2484
45. M Hamre, J Hedberg, J Buckley, et al. (1997) Langerhans cell histiocytosis: an exploratory epidemiologic study of 177 cases. Med Pediatr Oncol 28 92-97
46. S Bhatia, ME Nesbit Jr, RM Egeler, et al. (1997) Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr 130 774-784
47. M Arico, K Nichols, JA Whitlock, et al. (1999) Familial clustering of Langerhans cell histiocytosis. Br J Haematol 107 883-888
48. K McClain, H Jin, V Gresik and B Favara (1994) Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol 47 16-20
49. R Vassallo, JH Ryu, TV Colby, et al. (2000) Pulmonary Langerhans-cell histiocytosis. N Engl J Med 342 1969-1978
50. RM Egeler, JP Neglia, M Arico, et al. (1998) The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LCH-Malignancy Study Group of the Histiocyte Society. Hematol Oncol Clin North Am 12 369-378
51. MM Trebo, A Attarbaschi, G Mann, et al. (2005) Histiocytosis following T-acute lymphoblastic leukemia: a BFM study. Leuk Lymphoma 46 1735-1741
52. AL Feldman, F Berthold, RJ Arceci, et al. (2005) Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol 6 435-437
53. SJ Rodig, EG Payne, BA Degar, et al. (2008) Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol 83 116-121
54. V Broadbent, RM Egeler and ME Nesbit Jr (1994) Langerhans cell histiocytosis—clinical and epidemiological aspects. Br J Cancer Suppl 23 S11-S16
55. L Lichtenstein (1953) Histiocytosis X: integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schuller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol 56 84-102
56. C Nezelof, F Frileux-Herbet and J Cronier-Sachot (1979) Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases. Cancer 44 1824-1838
57. H Gadner, A Heitger, N Grois, et al. (1994) Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 23 72-80
58. ME Lahey (1975) Histiocytosis X: comparison of three treatment regimens. J Pediatr 87 179-183
59. DM Komp, J Herson, KA Starling, et al. (1981) A staging system for histiocytosis X: a Southwest Oncology Group Study. Cancer 47 798-800
60. J Donadieu, C Piguet, F Bernard, et al. (2004) A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer 43 770-776
61. C Titgemeyer, N Grois, M Minkov, et al. (2001) Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83 and -90 study. Med Pediatr Oncol 37 108-114
62. SK Lau, PG Chu and LM Weiss (2008) Immunohistochemical expression of langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol 32 615-619
63. K Chikwava and R Jaffe (2004) Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol 7 607-614
64. K Takahashi, T Isobe, Y Ohtsuki, et al. (1984) Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in human neoplasm and normal tissues. Virchows Arch B Cell Pathol Incl Mol Pathol 45 385-396
65. GS Pinkus, MA Lones, F Matsumura, et al. (2002) Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker. Am J Clin Pathol 118 335-343
66. G Bollini, JL Jouve, JC Gentet, et al. (1991) Bone lesions in histiocytosis X. J Pediatr Orthop 11 469-477
67. EM Azouz, G Saigal, MM Rodriguez and A Podda (2005) Langerhans cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol 35 103-115
68. KB Hoover, DI Rosenthal and H Mankin (2007) Langerhans cell histiocytosis. Skeletal Radiol 36 95-104
69. LA Binkovitz, RS Olshefski and BH Adler (2003) Coincidence FDG-PET in the evaluation of Langerhans cell histiocytosis: preliminary findings. Pediatr Radiol 33 598-602
70. R Blum, JF Seymour and RJ Hicks (2002) Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma 43 2155-2157
71. M Walia, P Paul, S Mishra and R Mehta (2004) Congenital Langerhans cell histiocytosis: the self-healing variety. J Pediatr Hematol Oncol 26 398-402
72. M Minkov, H Prosch, M Steiner, et al. (2005) Langerhans cell his­tiocytosis in neonates. Pediatr Blood Cancer 45 802-807
73. L Lau, B Krafchik, MM Trebo and S Weitzman (2006) Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 46 66-71
74. N Grois, D Prayer, H Prosch and H Lassmann (2005) Neuropathology of CNS disease in Langerhans cell histiocytosis. Brain 128 829-838
75. J Donadieu, MA Rolon, C Thomas, et al. (2004) Endocrine involvement in pediatric-onset Langerhans cell histiocytosis: a population-based study. J Pediatr 144 344-350
76. N Grois, U Potschger, H Prosch, et al. (2006) Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 46 228-233
77. M Maghnie, G Cosi, E Genovese, et al. (2000) Central diabetes insipidus in children and young adults. N Engl J Med 343 998-1007
78. H Prosch, N Grois, D Prayer, et al. (2004) Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatr Blood Cancer 43 594-599
79. F Ottaviano and JL Finlay (2003) Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 25 575-577
80. KE Rosenzweig, RJ Arceci and NJ Tarbell (1997) Diabetes insipidus secondary to Langerhans cell histiocytosis: is radiation therapy indicated? Med Pediatr Oncol 29 36-40
81. G Dhall, JL Finlay, IJ Dunkel, et al. (2008) Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 50 72-79
82. MA Barthez, E Araujo and J Donadieu (2000) Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors: results of a collaborative study. J Child Neurol 15 150-156
83. BE Favara, R Jaffe and RM Egeler (2002) Macrophage activation and hemophagocytic syndrome in Langerhans cell histiocytosis: report of 30 cases. Pediatr Dev Pathol 5 130-140
84. K McClain, NK Ramsay, L Robison, et al. (1983) Bone marrow invol­vement in histiocytosis X. Med Pediatr Oncol 11 167-171
85. M Minkov, U Potschger, N Grois, et al. (2007) Bone marrow assessment in Langerhans cell histiocytosis. Pediatr Blood Cancer 49 694-698
86. R Jaffe (2004) Liver involvement in the histiocytic disorders of childhood. Pediatr Dev Pathol 7 214-225
87. J Braier, M Ciocca, A Latella, et al. (2002) Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocytosis. Med Pediatr Oncol 38 178-182
88. SY Ha, P Helms, M Fletcher, et al. (1992) Lung involvement in Langerhans cell histiocytosis: prevalence, clinical features, and outcome. Pediatrics 89 466-469
89. J Braier, A Latella, B Balancini, et al. (2004) Outcome in children with pulmonary Langerhans cell Histiocytosis. Pediatr Blood Cancer 43 765-769
90. I Odame, P Li, L Lau, et al. (2006) Pulmonary Langerhans cell histiocytosis: a variable disease in childhood. Pediatr Blood Cancer 47 889-893
91. E Hait, M Liang, B Degar, et al. (2006) Gastrointestinal tract involvement in Langerhans cell histiocytosis: case report and literature review. Pediatrics 118 e1593-e1599
92. VR Nanduri, K Kelly, M Malone, et al. (1999) Colon involvement in Langerhans cell histiocytosis. J Pediatr Gastroenterol Nutr 29 462-466
93. F Geissmann, C Thomas, JF Emile, et al. (1996) Digestive tract involve­ment in Langerhans cell histiocytosis. The French Langerhans Cell Histiocytosis Study Group. J Pediatr 129 836-845
94. JD Laman, PJ Leenen, NE Annels, et al. (2003) Langerhans-cell histiocytosis: insight into DC biology. Trends Immunol 24 190-196
95. C Nauert, J Zornoza, A Ayala and TS Harle (1983) Eosinophilic granuloma of bone: diagnosis and management. Skeletal Radiol 10 227-235
96. JM Slater and OJ. Swarm (1980) Eosinophilic granuloma of bone. Med Pediatr Oncol 8 151-164
97. RB Womer, RB Raney Jr and GJ D’Angio (1985) Healing rates of treated and untreated bone lesions in histiocytosis X. Pediatrics 76 286-288
98. M Cohen, J Zornoza, A Cangir, et al. (1980) Direct injection of methylprednisolone sodium succinate in the treatment of solitary eosinophilic granuloma of bone: a report of 9 cases. Radiology 136 289-293
99. R Capanna, DS Springfield, P Ruggieri, et al. (1985) Direct cortisone injection in eosinophilic granuloma of bone: a preliminary report on 11 patients. J Pediatr Orthop 5 339-342
100. RM Egeler, RC Thompson Jr, PA Voute and ME Nesbit Jr (1992) Intralesional infiltration of corticosteroids in localized Langerhans cell histiocytosis. J Pediatr Orthop 12 811-814
101. MP Richter and GJ D’Angio (1981) The role of radiation therapy in the management of children with histiocytosis X. Am J Pediatr Hematol Oncol 3 161-163
102. R Gramatovici and GJ D’Angio (1988) Radiation therapy in soft-tissue lesions in histiocytosis X (Langerhans cell histiocytosis). Med Pediatr Oncol 16 259-262
103. RF Jubran, A Marachelian, F Dorey and M Malogolowkin (2005) Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer 45 37-42
104. SE Levine, JP Dormans, JS Meyer and TA Corcoran (1996) Langerhans cell histiocytosis of the spine in children. Clin Orthop Relat Res 288-293
105. MP Sheehan, DJ Atherton, V Broadbent and J Pritchard (1991) Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pediatr 119 317-321
106. OS Kwon, KH Cho and KY Song (1997) Primary cutaneous Langerhans cell histiocytosis treated with photochemotherapy. J Dermatol 24 54-56
107. S Munn and AC Chu (1998) Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am 12 269-286
108. YL Kwong, AC Chan and TK Chan (1997) Widespread skin-limited Langerhans cell histiocytosis: complete remission with interferon alfa. J Am Acad Dermatol 36 628-629
109. LV Avioli, JT Lasersohn and JM Lopresti (1963) Histiocytosis X (Schuller-Christian disease): a clinico-pathological survey, review of ten patients and the results of prednisone therapy. Medicine (Baltimore) 42 119-147
110. FR Beier, LG Thatcher and ME Lahey (1963) Treatment of Reticuloendotheliosis with vinblastine sulfate: preliminary report. J Pediatr 63 1087-1092
111. KA Starling, MH Donaldson, ME Haggard, et al. (1972) Therapy of histiocytosis X with vincristine, vinblastine, and cyclophosphamide. The Southwest Cancer Chemotherapy Study Group. Am J Dis Child 123 105-110
112. ME Lahey, RM Heyn, WA Newton Jr, et al. (1979) Histiocytosis X: clinical trial of chlorambucil: a report from Children's Cancer Study Group. Med Pediatr Oncol 7 197-203
113. B Jones, F Kung, L Chevalier, et al. (1974) Chemotherapy of reticuloendotheliosis: comparison of methotrexate plus prednisone vs. vincristine plus prednisone. Cancer 34 1011-1017
114. H Gadner, N Grois, M Arico, et al. (2001) A randomized trial of treatment for multisystem Langerhans cell histiocytosis. J Pediatr 138 728-734
115. A Ceci, M de Terlizzi, R Colella, et al. (1988) Etoposide in recurrent childhood Langerhans cell histiocytosis: an Italian cooperative study. Cancer 62 2528-2531
116. V Broadbent, J Pritchard and E Yeomans (1989) Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X). Med Pediatr Oncol 17 97-100
117. MB Viana, BM Oliveira, CM Silva and VH Rios Leite (1991) Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X). Med Pediatr Oncol 19 289-294
118. S Ladisch, H Gadner, M Arico, et al. (1994) LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. Med Pediatr Oncol 23 107-110
119. KC Stine, RL Saylors, S Saccente, et al. (2004) Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 43 81-84
120. KC Stine, RL Saylors, LL Williams and DL Becton (1997) 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol 29 288-292
121. S Weitzman, AS Wayne, R Arceci, et al. (1999) Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol 33 476-481
122. F Bernard, C Thomas, Y Bertrand, et al. (2005) Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 41 2682-2689
123. A Saven and C Burian (1999) Cladribine activity in adult Langerhans-cell histiocytosis. Blood 93 4125-4130
124. DM Komp, M Silva-Sosa, T Miale, et al. (1977) Evaluation of a MOPP-type regimen in histiocytosis X: a Southwest Oncology Group study. Cancer Treat Rep 61 855-859
125. RM Egeler, J de Kraker and PA Voute (1993) Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol 21 265-270
126. M Minkov, N Grois, A Heitger, et al. (2000) Treatment of multisystem Langerhans cell histiocytosis: results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 212 139-144
127. M Minkov, N Grois, A Heitger, et al. (2002) Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 39 581-585
128. H Gadner, N Grois, U Potschger, et al. (2008) Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 111 2556-2562
129. D Pollono, G Rey, A Latella, et al. (2007) Reactivation and risk of sequelae in Langerhans cell histiocytosis. Pediatr Blood Cancer 48 696-699
130. U Calming and JI Henter (1998) Elevated erythrocyte sedimentation rate and thrombocytosis as possible indicators of active disease in Langerhans cell histiocytosis. Acta Paediatr 87 1085-1087
131. M Minkov, M Steiner, U Potschger, et al. (2008) Reactivations in multisystem Langerhans cell histiocytosis: data of the International LCH Registry. J Pediatr June 25 (E-pub ahead of print)
132. RP Farran, E Zaretski and RM Egeler (2001) Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 23 54-56
133. K Arzoo, S Sadeghi and V Pullarkat (2001) Pamidronate for bone pain from osteolytic lesions in Langerhans-cell histiocytosis. N Engl J Med 345 225
134. KL McClain and CA Kozinetz (2007) A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 48 44-49
135. LM Lau, K Stuurman and S Weitzman (2008) Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors. Pediatr Blood Cancer 50 607-612
136. H Mottl, J Stary, M Chanova, et al. (2006) Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leuk Lymphoma 47 1881-1884
137. M Stoll, M Freund, H Schmid, et al. (1990) Allogeneic bone marrow transplantation for Langerhans cell histiocytosis. Cancer 66 284-288
138. HT Greinix, R Storb, JE Sanders and FB Petersen (1992) Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis. Bone Marrow Transplant 10 39-44
139. R Nagarajan, J Neglia, N Ramsay and KS Baker (2001) Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation. J Pediatr Hematol Oncol 23 629-632
140. A Suminoe, A Matsuzaki, H Hattori, et al. (2001) Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis. J Pediatr Hematol Oncol 23 633-636
141. V Akkari, J Donadieu, C Piguet, et al. (2003) Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant 31 1097-1103
142. M Steiner, S Matthes-Martin, A Attarbaschi, et al. (2005) Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 36 215-225
143. B Willis, A Ablin, V Weinberg, et al. (1996) Disease course and late sequelae of Langerhans cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol 14 2073-2082
144. R Haupt, V Nanduri, MG Calevo, et al. (2004) Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 42 438-444
145. C Bernstrand, K Cederlund, B Sandstedt, et al. (2001) Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol 36 459-468
146. VR Nanduri, L Lillywhite, C Chapman, et al. (2003) Cognitive outcome of long-term survivors of multisystem Langerhans cell histiocytosis: a single-institution, cross-sectional study. J Clin Oncol 21 2961-2967
147. E Mittheisz, R Seidl, D Prayer, et al. (2007) Central nervous system-related permanent consequences in patients with Langerhans cell histiocytosis. Pediatr Blood Cancer 48 50-56
148. S Imashuku, NA Okazaki, M Nakayama, et al. (2008) Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer 50 308-311
149. S Weitzman and R Jaffe (2005) Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer 45 256-264
150. R Caputo, AV Marzano, E Passoni and E Berti (2007) Unusual variants of non-Langerhans cell histiocytoses. J Am Acad Dermatol 57 1031-1045
151. SA Pileri, TM Grogan, NL Harris, et al. (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41 1-29
152. D Janssen and D Harms (2005) Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the Kiel pediatric tumor registry. Am J Surg Pathol 29 21-28
153. WH Burgdorf and B Zelger (2004) JXG, NF1, and JMML: alphabet soup or a clinical issue? Pediatr Dermatol 21 174-176
154. LP Dehner (2003) Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 27 579-593
155. DR Freyer, R Kennedy, BC Bostrom, et al. (1996) Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 129 227-237
156. S Auvin, JC Cuvellier, M Vinchon, et al. (2008) Subdural effusion in a CNS involvement of systemic juvenile xanthogranuloma: a case report treated with vinblastin. Brain Dev 30 164-168
157. E Unuvar, O Devecioglu, A Akcay, et al. (2007) Successful therapy of systemic xanthogranuloma in a child. J Pediatr Hematol Oncol 29 425-427
158. T Nakatani, A Morimoto, R Kato, et al. (2004) Successful treatment of congenital systemic juvenile xanthogranuloma with Langerhans cell histiocytosis-based chemotherapy. J Pediatr Hematol Oncol 26 371-374
159. J Rosai and RF Dorfman (1972) Sinus histiocytosis with massive lymphadenopathy: a pseudolymphomatous benign disorder. Analysis of 34 cases. Cancer 30 1174-1188
160. R Sanchez, RK Sibley, J Rosai and RF Dorfman (1981) The electron microscopic features of sinus histiocytosis with massive lymphadenopathy: a study of 11 cases. Ultrastruct Pathol 2 101-119
161. E Foucar, J Rosai and R Dorfman (1990) Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 7 19-73
162. E Foucar, J Rosai and RF Dorfman (1979) The ophthalmologic manifestations of sinus histiocytosis with massive lymphadenopathy. Am J Ophthalmol 87 354-367
163. E Foucar, J Rosai, RF Dorfman and RK Brynes (1982) The neurologic manifestations of sinus histiocytosis with massive lymphadenopathy. Neurology 32 365-372
164. E Foucar, J Rosai, RF Dorfman and JM Eyman (1984) Immunologic abnormalities and their significance in sinus histiocytosis with massive lymphadenopathy. Am J Clin Pathol 82 515-525
165. E Foucar, J Rosai and RF Dorfman (1984) Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry. Cancer 54 1834-1840
166. A Pulsoni, G Anghel, P Falcucci, et al. (2002) Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol 69 67-71
167. S Gordon and PR Taylor (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5 953-964
168. PR Taylor, L Martinez-Pomares, M Stacey, et al. (2005) Macrophage receptors and immune recognition. Annu Rev Immunol 23 901-944
169. G Kraal (1992) Cells in the marginal zone of the spleen. Int Rev Cytol 132 31-74
170. PR Taylor, S Zamze, RJ Stillion, et al. (2004) Development of a specific system for targeting protein to metallophilic macrophages. Proc Natl Acad Sci U S A 101 1963-1968
171. TB Geijtenbeek, PC Groot, MA Nolte, et al. (2002) Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens in vivo. Blood 100 2908-2916
172. YS Kang, S Yamazaki, T Iyoda, et al. (2003) SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake of the polysaccharide dextran. Int Immunol 15 177-186
173. LJ van der Laan, EA Dopp, R Haworth, et al. (1999) Regulation and functional involvement of macrophage scavenger receptor MARCO in clearance of bacteria in vivo. J Immunol 162 939-947
174. DA Hume, AP Robinson, GG MacPherson and S Gordon (1983) The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80: relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs. J Exp Med 158 1522-1536
175. S Goerdt and CE Orfanos (1999) Other functions, other genes: alternative activation of antigen-presenting cells. Immunity 10 137-142
176. S Gordon (2003) Alternative activation of macrophages. Nat Rev Immunol 3 23-35
177. DM Mosser (2003) The many faces of macrophage activation. J Leukoc Biol 73 209-212
178. GI Bechan, RM Egeler and RJ Arceci (2006) Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol 254 1-43
179. AB van oud Alblas and R van Furth (1979) Origin, kinetics, and characteristics of pulmonary macrophages in the normal steady state. J Exp Med 149 1504-1518
180. E Grage-Griebenow, HD Flad and M Ernst (2001) Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 69 11-20
181. F Geissmann, S Jung and DR Littman (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 71-82
182. K Matsuzaki, N Udagawa, N Takahashi, et al. (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246 199-204
183. JW Farquhar and AE Claireaux (1952) Familial haemophagocytic reticulosis. Arch Dis Child 27 519-525
184. VJ Marrian and NG Sanerkin (1963) Familial histiocytic reticulosis (familial haemophagocytic reticulosis). J Clin Pathol 16 65-69
185. P Nelson, A Santamaria, RL Olson and NC Nayak (1961) Generalized lymphohistiocytic infiltration: a familial disease not previously described and different from Letterer-Siwe disease and Chediak-Higashi syndrome. Pediatrics 27 931-950
186. RJ Risdall, RW McKenna, ME Nesbit, et al. (1979) Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 44 993-1002
187. RJ Risdall, RD Brunning, JI Hernandez and DH Gordon (1984) Bacteria-associated hemophagocytic syndrome. Cancer 54 2968-2972
188. AP Reiner and JL Spivak (1988) Hematophagic histiocytosis: a report of 23 new patients and a review of the literature. Medicine (Baltimore) 67 369-388
189. Writing Group of the Histiocyte Society (1987) Histiocytosis syndromes in children. Lancet 1 208-209
190. JI Henter, A Horne, M Arico, et al. (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 124-131
191. JI Henter, G Elinder, O Soder and A Ost (1991) Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 80 428-435
192. R Clementi, L Emmi, R Maccario, et al. (2002) Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood 100 2266-2267
193. M Allen, C De Fusco, F Legrand, et al. (2001) Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica 86 499-503
194. A Gencik, E Signer and H Muller (1984) Genetic analysis of familial erythrophagocytic lymphohistiocytosis. Eur J Pediatr 142 248-252
195. M Ohadi, MR Lalloz, P Sham, et al. (1999) Localization of a gene for familial hemophagocytic lymphohistiocytosis at chromosome 9q21.3-22 by homozygosity mapping. Am J Hum Genet 64 165-171
196. SE Stepp, R Dufourcq-Lagelouse, F Le Deist, et al. (1999) Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286 1957-1959
197. A Trizzino, U zur Stadt, I Ueda, et al. (2008) Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet 45 15-21
198. SE Stepp, PA Mathew, M Bennett, et al. (2000) Perforin: more than just an effector molecule. Immunol Today 21 254-256
199. KA Risma, RW Frayer, AH Filipovich and J Sumegi (2006) Aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest 116 182-192
200. U zur Stadt, S Schmidt, B Kasper, et al. (2005) Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 14 827-834
201. J Feldmann, I Callebaut, G Raposo, et al. (2003) Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115 461-473
202. E Rudd, YT Bryceson, C Zheng, et al. (2008) Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis. J Med Genet 45 134-141
203. D Zikich, A Mezer, F Varoqueaux, et al. (2008) Vesicle priming and recruitment by ubMunc13-2 are differentially regulated by calcium and calmodulin. J Neurosci 28 1949-1960
204. J Basu, A Betz, N Brose and C Rosenmund (2007) Munc13-1 C1 domain activation lowers the energy barrier for synaptic vesicle fusion. J Neurosci 27 1200-1210
205. YT Bryceson, E Rudd, C Zheng, et al. (2007) Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 110 1906-1915
206. U Zur Stadt, K Beutel, S Kolberg, et al. (2006) Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat 27 62-68
207. K Goransdotter Ericson, B Fadeel, S Nilsson-Ardnor, et al. (2001) Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet 68 590-597
208. E Rudd, K Goransdotter Ericson, C Zheng, et al. (2006) Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet 43 e14
209. CM Rubin, BA Burke, RW McKenna, et al. (1985) The accelerated phase of Chédiak-Higashi syndrome: an expression of the virus-associated hemophagocytic syndrome? Cancer 56 524-530
210. G Menasche, E Pastural, J Feldmann, et al. (2000) Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 25 173-176
211. M Kumar, K Sackey, F Schmalstieg, et al. (2001) Griscelli syndrome: rare neonatal syndrome of recurrent hemophagocytosis. J Pediatr Hematol Oncol 23 464-468
212. M Duval, O Fenneteau, V Doireau, et al. (1999) Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. J Pediatr 134 236-239
213. M Arico, S Imashuku, R Clementi, et al. (2001) Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 97 1131-1133
214. M Neeft, M Wieffer, AS de Jong, et al. (2005) Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 16 731-741
215. AJ Coffey, RA Brooksbank, O Brandau, et al. (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20 129-135
216. D Torrents, J Mykkanen, M Pineda, et al. (1999) Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. Nat Genet 21 293-296
217. S Rajagopala, U Dutta, KS Chandra, et al. (2008) Visceral leishmaniasis associated hemophagocytic Lymphohistiocytosis: case report and systematic review. J Infect 56 381-388
218. GE Janka (1983) Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 140 221-230
219. JA Yin, TO Kumaran, GW Marsh, et al. (1983) Complete recovery of histiocytic medullary reticulosis-like syndrome in a child with acute lymphoblastic leukemia. Cancer 51 200-202
220. TE Petterson, AA Bosco and RJ Cohn (2008) Aggressive natural killer cell leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 50 654-657
221. H Tong, Y Ren, H Liu, et al. (2008) Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma 49 81-87
222. M Hadchouel, AM Prieur and C Griscelli (1985) Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 106 561-566
223. T Avcin, SM Tse, R Schneider, et al. (2006) Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr 148 683-686
224. S Sawhney, P Woo and KJ Murray (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85 421-426
225. A Ravelli (2002) Macrophage activation syndrome. Curr Opin Rheumatol 14 548-552
226. MM Hazen, AL Woodward, I Hofmann, et al. (2008) Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 58 567-570
227. R Donn, S Ellison, R Lamb, et al. (2008) Genetic loci contributing to hemophagocytic lymphohistiocytosis do not confer susceptibility to systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 869-874
228. LE Ansbacher, BH Singsen, MW Hosler, et al. (1983) Familial erythrophagocytic lymphohistiocytosis: an association with serum lipid abnormalities. J Pediatr 102 270-273
229. RE Brown, WP Bowman, CA D’Cruz, et al. (1987) Endoperoxidation, hyperprostaglandinemia, and hyperlipidemia in a case of erythrophagocytic lymphohistiocytosis: reversal with VP-16 and indomethacin. Cancer 60 2388-2393
230. PD McClure, P Strachan and EF Saunders (1974) Hypofibrinogenemia and thrombocytopenia in familial hemophagocytic reticulosis. J Pediatr 85 67-70
231. L Rooms, N Fitzgerald and KL McClain (2003) Hemophagocytic lymphohistiocytosis masquerading as child abuse: presentation of three cases and review of central nervous system findings in hemophagocytic lymphohistiocytosis. Pediatrics 111 e636-e640
232. N Esumi, S Ikushima, S Hibi, et al. (1988) High serum ferritin level as a marker of malignant histiocytosis and virus-associated hemophagocytic syndrome. Cancer 61 2071-2076
233. N Esumi, S Ikushima, S Todo and S Imashuku (1987) Hyperferritinemia in malignant histiocytosis and virus-associated hemophagocytic syndrome. N Engl J Med 316 346-347
234. CE Allen, X Yu, CA Kozinetz and KL McClain (2008) Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 50 1227-1235
235. JI Henter (2008) Pronounced hyperferritinemia: expanding the field of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 50 1127-1129
236. G Zandman-Goddard and Y Shoenfeld (2007) Ferritin in autoimmune diseases. Autoimmun Rev 6 457-463
237. M Arico, G Janka, A Fischer, et al. (1996) Hemophagocytic Lymphohistiocytosis: report of 122 children from the International Registry, FHL Study Group of the Histiocyte Society. Leukemia 10 197-203
238. Y Kataoka, S Todo, Y Morioka, et al. (1990) Impaired natural killer activity and expression of interleukin-2 receptor antigen in familial erythrophagocytic lymphohistiocytosis. Cancer 65 1937-1941
239. JI Henter, G Elinder, O Soder, et al. (1991) Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78 2918-2922
240. S Imashuku, S Hibi, F Fujiwara and S Todo (1996) Hyper-interleukin (IL)-6-naemia in haemophagocytic lymphohistiocytosis. Br J Haematol 93 803-807
241. DM Komp, J McNamara and P Buckley (1989) Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 73 2128-2132
242. N Perez, JL Virelizier, F Arenzana-Seisdedos, et al. (1984) Impaired natural killer activity in lymphohistiocytosis syndrome. J Pediatr 104 569-573
243. EM Schneider, I Lorenz, M Muller-Rosenberger, et al. (2002) Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 100 2891-2898
244. A Horne, C Zheng, I Lorenz, et al. (2005) Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance. Br J Haematol 129 658-666
245. S Imashuku, N Hyakuna, T Funabiki, et al. (2002) Low natural killer activity and central nervous system disease as a high-risk prognostic indicator in young patients with hemophagocytic lymphohistiocytosis. Cancer 94 3023-3031
246. E Ishii, I Ueda, R Shirakawa, et al. (2005) Genetic subtypes of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. Blood 105 3442-3448
247. S Marcenaro, F Gallo, S Martini, et al. (2006) Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 108 2316-2323
248. HW Goo and YC Weon (2007) A spectrum of neuroradiological findings in children with haemophagocytic lymphohistiocytosis. Pediatr Radiol 37 1110-1117
249. A Horne, H Trottestam, M Arico, et al. (2008) Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 140 327-335
250. M Arico, D Caselli and GR Burgio (1989) Familial hemophagocytic lymphohistiocytosis: clinical features. Pediatr Hematol Oncol 6 247-251
251. E Haddad, ML Sulis, N Jabado, et al. (1997) Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. Blood 89 794-800
252. K Rostasy, R Kolb, D Pohl, et al. (2004) CNS disease as the main manifestation of hemophagocytic lymphohistiocytosis in two children. Neuropediatrics 35 45-49
253. JI Henter and I Nennesmo (1997) Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. J Pediatr 130 358-365
254. DR Ambruso, T Hays, WJ Zwartjes, et al. (1980) Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16-213. Cancer 45 2516-2520
255. MC Perry, EG Harrison Jr, EO Burgert Jr and GS Gilchrist (1976) Familial erythrophagocytic lymphohistocytosis: report of two cases and clinicopathologic review. Cancer 38 209-218
256. A Fischer, JL Virelizier, F Arenzana-Seisdedos, et al. (1985) Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate, and cranial irradiation. Pediatrics 76 263-268
257. CS Alvarado, GR Buchanan, TH Kim, et al. (1986) Use of VP-16-213 in the treatment of familial erythrophagocytic lymphohistiocytosis. Cancer 57 1097-1100
258. JI Henter, G Elinder, Y Finkel and O Soder (1986) Successful induction with chemotherapy including teniposide in familial erythrophagocytic lymphohistiocytosis. Lancet 2 1402
259. A Fischer, N Cerf-Bensussan, S Blanche, et al. (1986) Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr 108 267-270
260. S Blanche, M Caniglia, D Girault, et al. (1991) Treatment of hemophagocytic lymphohistiocytosis with chemotherapy and bone marrow transplantation: a single-center study of 22 cases. Blood 78 51-54
261. KS Baker, CA DeLaat, M Steinbuch, et al. (1997) Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. Blood 89 3857-3863
262. BJ Loechelt, M Egeler, AH Filipovich, et al. (1994) Immunosuppression: preliminary results of alternative maintenance therapy for familial hemophagocytic lymphohistocytosis (FHL). Med Pediatr Oncol 22 325-328
263. EM Abella, J Artrip, K Schultz and Y Ravindranath (1997) Treatment of familial erythrophagocytic lymphohistiocytosis with cyclosporine A. J Pediatr 130 467-470
264. JI Henter, A Samuelsson-Horne, M Arico, et al. (2002) Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100 2367-2373
265. JL Stephan, J Donadieu, F Ledeist, et al. (1993) Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood 82 2319-2323
266. N Mahlaoui, M Ouachee-Chardin, G de Saint Basile, et al. (2007) Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 120 e622-e628
267. T Teramura, Y Tabata, T Yagi, et al. (2002) Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma 43 173-179
268. S Imashuku, S Hibi, T Ohara, et al. (1999) Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood 93 1869-1874
269. S Imashuku, T Teramura, K Kuriyama, et al. (2002) Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Int J Hematol 75 174-177
270. S Imashuku, K Kuriyama, T Teramura, et al. (2001) Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 19 2665-2673
271. S Imashuku, T Teramura, H Tauchi, et al. (2004) Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica 89 183-188
272. MC Milone, DE Tsai, RL Hodinka, et al. (2005) Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105 994-996
273. NJ Balamuth, KE Nichols, M Paessler and DT Teachey (2007) Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 29 569-573
274. H Lackner, C Urban, P Sovinz, et al. (2008) Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children. Haematologica 93 291-294
275. R Mouy, JL Stephan, P Pillet, et al. (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 129 750-754
276. S Prahalad, KE Bove, D Dickens, et al. (2001) Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 28 2120-2124
277. T Henzan, K Nagafuji, H Tsukamoto, et al. (2006) Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 81 59-61
278. KS Baker, AH Filipovich, TG Gross, et al. (2008) Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant 42 175-180
279. N Jabado, ER de Graeff-Meeder, M Cavazzana-Calvo, et al. (1997) Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. Blood 90 4743-4748
280. A Horne, G Janka, R Maarten Egeler, et al. (2005) Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 129 622-630
281. N Cooper, K Rao, K Gilmour, et al. (2006) Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 107 1233-1236